Perspectives in Lung Cancer Care Virtual Meeting

August 6th, 2021: 10:30 – 11:30am PT, 1:30 – 2:30pm ET

Join Drs. Edgardo Santos, Snehal Thakkar, and Kristin Gunderson at PLCC 2021 for a symposium entitled: “What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care”.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Expanded Medicare Coverage

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score assay is fully covered by Medicare for localized prostate cancer patients.

AUA 2021: Live in Las Vegas, NV

September 10th - 13th, 2021

Visit us at our booth to learn more about how the Oncotype test portfolio delivers essential genomic information to help guide treatment decisions for your localized to advanced prostate cancer patients.

20-Year Outcomes

Oncotype DX Genomic Prostate Score

New follow-up data suggests that the GPS result may be associated with prostate cancer outcomes for up to 20 years after diagnosis.
Making cancer care smarter.®

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.